These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 17485499)

  • 1. Inhibition of isolated Mycobacterium tuberculosis fatty acid synthase I by pyrazinamide analogs.
    Ngo SC; Zimhony O; Chung WJ; Sayahi H; Jacobs WR; Welch JT
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2430-5. PubMed ID: 17485499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of Mycobacterium smegmatis expressing the Mycobacterium tuberculosis fatty acid synthase I (fas1) gene.
    Zimhony O; Vilchèze C; Jacobs WR
    J Bacteriol; 2004 Jul; 186(13):4051-5. PubMed ID: 15205406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis.
    Zimhony O; Cox JS; Welch JT; Vilchèze C; Jacobs WR
    Nat Med; 2000 Sep; 6(9):1043-7. PubMed ID: 10973326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analogs of the antituberculous agent pyrazinamide are competitive inhibitors of NADPH binding to M. tuberculosis fatty acid synthase I.
    Sayahi H; Pugliese KM; Zimhony O; Jacobs WR; Shekhtman A; Welch JT
    Chem Biodivers; 2012 Nov; 9(11):2582-96. PubMed ID: 23161636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pyrazinoic acid and its n-propyl ester inhibit fatty acid synthase type I in replicating tubercle bacilli.
    Zimhony O; Vilchèze C; Arai M; Welch JT; Jacobs WR
    Antimicrob Agents Chemother; 2007 Feb; 51(2):752-4. PubMed ID: 17101678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pyrazinamide, but not pyrazinoic acid, is a competitive inhibitor of NADPH binding to Mycobacterium tuberculosis fatty acid synthase I.
    Sayahi H; Zimhony O; Jacobs WR; Shekhtman A; Welch JT
    Bioorg Med Chem Lett; 2011 Aug; 21(16):4804-7. PubMed ID: 21775138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutually exclusive genotypes for pyrazinamide and 5-chloropyrazinamide resistance reveal a potential resistance-proofing strategy.
    Baughn AD; Deng J; Vilchèze C; Riestra A; Welch JT; Jacobs WR; Zimhony O
    Antimicrob Agents Chemother; 2010 Dec; 54(12):5323-8. PubMed ID: 20876380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of pyrazinamide on fatty acid synthesis by whole mycobacterial cells and purified fatty acid synthase I.
    Boshoff HI; Mizrahi V; Barry CE
    J Bacteriol; 2002 Apr; 184(8):2167-72. PubMed ID: 11914348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of n-propyl pyrazinoate against pyrazinamide-resistant Mycobacterium tuberculosis: investigations into mechanism of action of and mechanism of resistance to pyrazinamide.
    Speirs RJ; Welch JT; Cynamon MH
    Antimicrob Agents Chemother; 1995 Jun; 39(6):1269-71. PubMed ID: 7574514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pyrazinamide and Pyrazinoic Acid Derivatives Directed to Mycobacterial Enzymes Against Tuberculosis.
    Corrêa MF; Fernandes JP
    Curr Protein Pept Sci; 2016; 17(3):213-9. PubMed ID: 26427385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipophilic pyrazinoic acid amide and ester prodrugs stability, activation and activity against M. tuberculosis.
    Simões MF; Valente E; Gómez MJ; Anes E; Constantino L
    Eur J Pharm Sci; 2009 Jun; 37(3-4):257-63. PubMed ID: 19491013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural basis for targeting the ribosomal protein S1 of Mycobacterium tuberculosis by pyrazinamide.
    Yang J; Liu Y; Bi J; Cai Q; Liao X; Li W; Guo C; Zhang Q; Lin T; Zhao Y; Wang H; Liu J; Zhang X; Lin D
    Mol Microbiol; 2015 Mar; 95(5):791-803. PubMed ID: 25430994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Nutrient starved incubation conditions enhance pyrazinamide activity against Mycobacterium tuberculosis].
    Chen ZF; Huang Q; Li YY; Zhang Y; Ren Y; Li KS; Fu ZJ; Xu SQ
    Zhonghua Jie He He Hu Xi Za Zhi; 2007 May; 30(5):359-62. PubMed ID: 17651643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The paradox of pyrazinamide: an update on the molecular mechanisms of pyrazinamide resistance in Mycobacteria.
    Singh P; Mishra AK; Malonia SK; Chauhan DS; Sharma VD; Venkatesan K; Katoch VM
    J Commun Dis; 2006 Mar; 38(3):288-98. PubMed ID: 17373362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mycobacterium tuberculosis isolates from Rio de Janeiro reveal unusually low correlation between pyrazinamide resistance and mutations in the pncA gene.
    Bhuju S; Fonseca Lde S; Marsico AG; de Oliveira Vieira GB; Sobral LF; Stehr M; Singh M; Saad MH
    Infect Genet Evol; 2013 Oct; 19():1-6. PubMed ID: 23770140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does pyrazinoic acid as an active moiety of pyrazinamide have specific activity against Mycobacterium tuberculosis?
    Heifets LB; Flory MA; Lindholm-Levy PJ
    Antimicrob Agents Chemother; 1989 Aug; 33(8):1252-4. PubMed ID: 2508544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative structure-activity relationships for the in vitro antimycobacterial activity of pyrazinoic acid esters.
    Bergmann KE; Cynamon MH; Welch JT
    J Med Chem; 1996 Aug; 39(17):3394-400. PubMed ID: 8765523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nutrient-starved incubation conditions enhance pyrazinamide activity against Mycobacterium tuberculosis.
    Huang Q; Chen ZF; Li YY; Zhang Y; Ren Y; Fu Z; Xu SQ
    Chemotherapy; 2007; 53(5):338-43. PubMed ID: 17785970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the BacT/ALERT PZA kit in comparison with the BACTEC 460TB PZA for testing Mycobacterium tuberculosis susceptibility to pyrazinamide.
    Aragón LM; Garrigó M; Moreno C; Español M; Coll P
    J Antimicrob Chemother; 2007 Sep; 60(3):655-7. PubMed ID: 17615155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A study of the bacteriophage-based assay for the detection of pyrazinamide resistance in Mycobacterium tuberculosis].
    Ao JP; Chen JW; Hu ZY; Li JN; Wang J; Wang Q; Cui ZL; Zhang WH; Wong XH
    Zhonghua Jie He He Hu Xi Za Zhi; 2006 Sep; 29(9):625-8. PubMed ID: 17129472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.